1. Home
  2. INLF vs IMRN Comparison

INLF vs IMRN Comparison

Compare INLF & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INLF

INLIF LIMITED

HOLD

Current Price

$0.52

Market Cap

10.6M

Sector

Industrials

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.78

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLF
IMRN
Founded
2016
1994
Country
China
Australia
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
12.0M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
INLF
IMRN
Price
$0.52
$0.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
562.6K
1.3M
Earning Date
09-29-2025
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,332,282.00
$4,777,422.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
33.11
48.63
52 Week Low
$0.48
$0.68
52 Week High
$21.00
$2.48

Technical Indicators

Market Signals
Indicator
INLF
IMRN
Relative Strength Index (RSI) 29.49 25.44
Support Level $0.50 $0.68
Resistance Level $0.54 $0.95
Average True Range (ATR) 0.03 0.06
MACD -0.00 -0.00
Stochastic Oscillator 16.86 30.65

Price Performance

Historical Comparison
INLF
IMRN

About INLF INLIF LIMITED

INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The company portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: